End-of-day quote
Other stock markets
|
||
- EUR | - |
26/03 | GT Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
01/02 | GT Biopharma to Conduct 1-for-30 Reverse Stock Split; Shares Fall | MT |
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
Michael Breen
CEO | Chief Executive Officer | 62 | 13/21/13 |
Manu Ohri
DFI | Director of Finance/CFO | 67 | 18/22/18 |
Jeffrey Miller
PRN | Corporate Officer/Principal | - | 14/22/14 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 78 | 01/23/01 | |
Bruce Wendel
BRD | Director/Board Member | 70 | 11/20/11 |
Rajesh Shrotriya
BRD | Director/Board Member | 79 | 13/21/13 |
Michael Breen
CEO | Chief Executive Officer | 62 | 13/21/13 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 96,230 | 0 | 0 | 83.75 % |
Stock B | 1 | 1,380,633 | 1,236,809 ( 89.58 %) | 0 |
Company contact information
GT Biopharma, Inc.
8000 Marina Boulevard Suite 100
94005, Brisbane
+415 919 4040
http://www.gtbiopharma.comSector
1st Jan change | Capi. | |
---|---|---|
+32.36% | 695B | |
+26.51% | 568B | |
-4.40% | 361B | |
+19.46% | 330B | |
+3.50% | 283B | |
+16.34% | 239B | |
+6.68% | 204B | |
-9.08% | 198B | |
+8.62% | 168B |
- Stock Market
- Equities
- GTBP Stock
- Stock
- Company Oxis International